Nuvilex Contracts with Austrianova for cGMP-Compliant Cell-in-a-Box Encapsulation of Cells for Clinical Trials Manufacturing Agreement Signed by Nuvilex and Austrianova

Nuvilex Contracts with Austrianova for

cGMP-Compliant Cell-in-a-Box Encapsulation of Cells for Clinical Trials

Manufacturing Agreement Signed by Nuvilex

SILVER SPRING, MD, March 20, 2013 (GLOBE NEWSWIRE) -- Nuvilex,

Inc. (OTCQB: NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases,

announced today that it has contracted with Austrianova Singapore (Austrianova), a subsidiary of SG Austria in which Nuvilex is

a partial owner, to perform the cGMP (Good Manufacturing Practices)-compliant encapsulation of live cells to be used for Nuvilex's

clinical trials in patients with advanced, inoperable pancreatic cancer and associated conditions and other types of cancer. A

manufacturing agreement that covers all aspects of the production of the encapsulated live cells has been signed by Nuvilex and

An initial payment has been made by Nuvilex to Austrianova as

part of a "set-up fee" to encapsulate the live cells required by Nuvilex for use in its clinical trials. Austrianova

was contracted to perform the encapsulation because it developed and matured the entire Cell-in-a-Box cellulose-based

live-cell encapsulation process. Austrianova is considered the world's foremost expert in this unique and proprietary technology.

The Cell-in-a-Box encapsulation of live cells

capable of converting the anticancer prodrug ifosfamide into its cancer-killing form will be performed at Austrianova's manufacturing

facilities being established in Thailand. The cells that will be encapsulated are those that result from the cell cloning currently

underway by Nuvilex at Inno Biologics' facilities in Malaysia. The capsules containing the live cancer prodrug-activating

cells will be implanted in patients with advanced, inoperable pancreatic cancer and, together with ifosfamide, will form Nuvilex's

novel treatment for this deadly disease. In addition, the encapsulated cells will be used in connection with Nuvilex's planned

clinical trials that are related to pancreatic and other forms of cancer. All steps of the encapsulation process will strictly

adhere to cGMP-standards.

The CEO and President of Nuvilex, Kenneth L. Waggoner, commented,

"The signing of the manufacturing agreement with Austrianova for the cGMP-compliant encapsulation of the live cells that

will be used in our late-phase clinical trials in patients with advanced, inoperable pancreatic cancer and for other newly planned

clinical trials represents an indispensable step as Nuvilex continues to prepare for conducting these essential trials. Austrianova

is the only company in the world with the in-house' knowledge to perform the cellulose-based live-cell encapsulation

process known as Cell-in-a-Box '. We are very pleased that Professor Dr. Walter H. G nzburg and Dr. Brian

Salmons, who developed the Cell-in-a-Box technology, have agreed to work closely with us in our endeavors."

Nuvilex is a biotechnology company focused on developing and

preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation

technology, known as Cell-in-a-Box . This unique and patented technology will be used as a platform upon which treatments

for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment

for pancreatic cancer involves the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells which convert

ifosfamide into its active or "cancer-killing" form. Nuvilex is also involved in clinical trials related to other aspects

of pancreatic and other forms of cancer. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development

of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit

the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of cannabinoids against cancers

while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides

Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those

of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.

This press release may contain forward-looking statements regarding

Nuvilex and its future events and results that involve inherent risks and uncertainties. The words "anticipate,"

"believe," "estimate," "expect," "intend," "plan" and similar expressions,

as they relate to Nuvilex or its management, are intended to identify forward-looking statements. Important factors, many

of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking

statements include Nuvilex's ability to continue as a going concern, delays in clinical trials or flaws or defects regarding

its products, changes in relevant legislation or regulatory requirements, uncertainty of protection of Nuvilex's intellectual

property and Nuvilex's continued ability to raise capital. Nuvilex does not assume any obligation to update any

of these forward-looking statements.

More information about Nuvilex and

Medical Marijuana Sciences can be found at www.nuvilex.com and www.medicalmarijuanasciences.com.

It can also be obtained by contacting Investor Relations.

Investor Relations Contacts:

Marmel Communications, LLC

Telephone: 702.434.8692

Telephone: 218.839.9051